Parkinson's disease: Genetics and beyond

Current Neuropharmacology

Volumn 5, Issue 2, 2007, Pages 99-113

  Inamdar, N N ^a   Arulmozhi, D K ^b   Tandon, A ^c   Bodhankar, S L ^b  

^a Allana College of Pharmacy   (India)

^b BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Synuclein; Lewy bodies; Mitochondrial dysfunction; Parkin; Parkinson's disease; Pathophysiology; Protein aggregation

Indexed keywords

3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE; ADENOSINE A2A RECEPTOR ANTAGONIST; ADROGOLIDE; ALPHA SYNUCLEIN; AMANTADINE; AMPA RECEPTOR ANTAGONIST; ANTIPARKINSON AGENT; BENSERAZIDE; CARBIDOPA; CASPASE INHIBITOR; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DJ 1 PROTEIN; DOPAMINE RECEPTOR STIMULATING AGENT; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE (NADP)(PHOSPHORYLATING); LEUCINE RICH REPEAT KINASE 2; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROTROPHIC FACTOR; PARKIN; PHOSPHOTRANSFERASE; PROTEIN P53 INHIBITOR; PROTEIN PINK1; ROLIGOTINE; SEROTONIN AGONIST; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TOLCAPONE; UBIQUITIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATHETOSIS; AUTOPHAGY; CELL SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; DELIRIUM; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DYSKINESIA; DYSTONIA; ENVIRONMENTAL FACTOR; EXCITOTOXICITY; GENE MUTATION; GENE THERAPY; HEREDITY; HUMAN; IMMUNOTHERAPY; INFLAMMATION; LIVER TOXICITY; MANIA; MITOCHONDRIAL DNA DISORDER; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; ON OFF PHENOMENON; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PSYCHOSIS; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 34347405256     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015907780866893     Document Type: Review

References (292)

1. Abad, V.C., Guilleminault, C. (2004) Review of rapid eye movement behavior sleep disorders. Curr. Neurol. Neurosci. Rep., 4, 157-63.
2. Abou-Sleiman, P.M., Healy, D.G., Quinn, N., Lees, A.J., Wood, N.W. (2003) The role of pathogenic DJ-s1 mutations in Parkinson's disease. Ann. Neurol., 54, 283-286.
3. Agid, Y. (1998) Levodopa: is toxicity a myth? Neurology, 50, 858-863.
4. Aharan-Peretz, J., Rosnbaum, H., Gershani-Baruch, R. (2004) Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N. Eng. J. Med., 351, 1972-1977.
5. Ahn, B.H., Rhim, H., Kim, S.Y., Sung, Y.M., Lee, M.Y., Choi, J.Y. (2002) α-synuclein interacts with phospholipase D isozymes and inhibits pervandate induced phospholipase D activation in human embroyo in kidney-293 cells. J. Biol. Chem., 277, 12334-12342.
6. Allam, M.F., Del Castillo, A.S., Navajas, R.F. (2005) Parkinson's disease risk factors: genetic, environmental or both? Neurol. Res., 27, 206-208.
7. Armstrong, M., Daly, A.K., Cholerten, S., Bateman, D.N., Idle, J.R. (1992) Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet, 339, 1017-1018.
8. Asanuma, M., Miyazaki, I., Diaz-Corlaes, F.J., Ogawa, N. (2004) Quinone formation as dopaminergic neuron-specific oxidative stress in the pathogenesis of sporadic PD and neurotoxin induced parkinsonism. Acta Med. Okayama, 58, 221-233.
9. Bandopadhay, R., Kingsbury, A.E., Cookson, M.R., Reid, A.R., Evans, I.M., Hope, A.D., Pittman, A.M., Lashley, T. (2004) The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain, 127, 420-430.
10. Barnes, N.M., Sharp, T. (1999) A review of central 5-HT receptors and their functions. Neuropharmacology, 38, 10083-11152.
11. Bartoszyk, G.D., Van Amsterdam, C., Greiner, H.E., Rauternberg, W., Russ, H., Seyfried, C.A. (2004) Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand 1.Neurochemical Profile. J. Neural Trans., 111, 113-126.
12. Beal, M.F. (1998) Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann. Neurol., 44, S110-S114.
13. Bennett, M.C., Bishop, J.F., Leng, Y., Chock, P.B., Chase, T.N., Mouradian, M.M. (1999) Degradation of α-synuclein by proteasome. J. Biol. Chem., 274, 33855-33858.
14. Bennett, M.C. (2005) The role of α-synuclein in neurodegerative diseases. Pharmacol. Ther., 105, 311-331.
15. Berg, D., Gerlach, M., Youdin, M.B., Double, K.L. (2001) Brain iron pathways and their relevance to Parkinson's disease. J. Neurochem., 79, 225-236.
16. Berman, S.B., Hastings, T.G. (1997) Inhibition of glutamate transport in synaptosomes by dopamine oxidation and reactive oxygen species. J. Neurochem., 69, 1185-1195.
17. Betarbet, R., Sherer, T.B., Greenamyre, J.T. (2005) Ubiquitin-proteasome system and Parkinson's disease. Expt. Neurol., 191, S17-S27.
18. Bharath, S., Hsu, M., Kaur, D., Rajgopalan, S., Anderson, J.K. (2002) Glutathione iron and Parkinson's disease. Biochem. Pharm., 64, 1037-1048.
19. Blackburn, T. (2004) Serotonergic agents and Parkinson's disease. Drug Discov. Today, 1, 35-41.
20. Blanchet, P.J., Metman, L.V., Chase, T.N. (2003) Renaissance of amantadine in the treatment of Parkinson's disease. Adv. Neurol., 91, 251-257.
21. Breidert, T., Calebert, J., Heneka, M.T., Landreth, G., Launay, J.M., Hirsch, E.C. (2002) Protective action of the peroxisome proliferator activated receptor γ agonist pioglitazone in mouse models of Parkinson's disease. J. Neurochem., 82, 615-624.
22. Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurolo, J. (2002) Inherent toxicity of aggregates implies a common mechanism of protein misfolding diseases. Nature, 416, 507-511.
23. Calan, F., Rajput, A.H., Homkiewiez, O., Bedard, P.J., Dipalo, T. (2003) Levodopa- induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol. Disord., 14, 404-416.
24. Calne, D.B., Snow, B.J., Lee, C. (1992) Criteria for Parkinson's disease. Adv. Neurol., 32, S121-S127.
25. Canet-Aviles, R.M., Wilson, M.A., Miller, D.W. (2004) The PD protein DJ-1 is neuroprotective due to cystein-sulfinic acid driven mitochondrial localization. Proc. Natl. Acad. Sci. USA, 101, 9103-9108.
26. Cassarino, D.S., Benneltt Jr, J.P. (1999) An evaluation of the role of mitochondrial mutations and oxidative pathology protective nuclear responses and cell death in neurodegeneration. Brain Res. Rev., 29, 1-25.
27. Castellani, R.J., Perry, G., Siedlak, S.L., Nunomura, A., Shimohama, S., Zhang, J. (2002) Hydroxnoneal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci. Lett., 319, 25-28.
28. Chandra, S., Chen, X., Rizo, J., Jahn, R., Sudho, T.C. (2003) A broken α-helix in folded α-synuclein. J. Biol. Chem., 278, 15313-15318.
29. Chartier-Harlim, M.C. (2004) α-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet, 364, 1167-1169.
30. Chase, T.N. (1998) Levodopa therapy: consequences of nonphysiologic replacement of dopamine. Neurology, 50, S17-S25.
31. Chen, H., Zang, S.M., Herman, M.A., Schwarzschild, M.A., Willet, W.C., Colditz, G.A., Speizer, F.E., Ascherio, A. (2003) Nonsteroidal antiinflammatory drugs and the risk of Parkinson's disease. Arch. Neurol., 60, 1059-1064.
32. Chen, J.J. (2004) Anxiety, depression and psychosis in Parkinson's disease. Unmet needs and treatment challenges. Neurol. Clin., 41, 15-23.
33. Chen, Q., He, Y., Keyi, Y. (2005) Gene therapy for Parkinson's disease: progress and challenges. Curr. Gene Ther., 5, 71-80.
34. Choudhary, S., Behari, M., Dihana, M., Swaminathann, P.J., Govindappa, S.T. (2006) Parkin mutations in familial and sporadic Parkinson's disease among Indians. Parkinsonism Relat. Disord., 12, 239-45.
35. Chung, K.K., Zhang, Y., Lim, K.L., Tanaka, Y., Huang, H., Gao, J., Ross, C.A., Dawson, T.M. (2001) Parkin ubiquitinates the α-synuclein interacting protein, synphilin-1: implications for Lewy body formation in Parkinson's disease. Nat. Med., 10, 1144-1150.
36. Coldwell, M.C., Haga, J., Middlemiss, D., Telloch, I., Boyfield, I. (1997) Ropinirole is a D3-selective agonist at cloned human D2 analog D3 and D4 receptors in functional studies using microphysiometry. Br. J. Pharmacol., 119, S346 (abstract).
37. Conway, K., Rochet, J.C., Bieganski, R.M., Lanbury, P.T.J. (2001) Kinetic stabilization of α-synuclein protofibril by a dopamine-α-synuclein adduct. Science, 294, 1346-1349.
38. Crossman, A.R. (1990) A hypothesis on the pathophysiological mechanisms that underlie levodopa or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for the future strategies in treatment. Mov. Disord., 5, 100-108.
39. Cuervo, A.M., Stefani, L., Fredenburg, R., Lansburry, P.T., Sulzer, D. (2004) Impaired degradation of mutant α-synuclein by chaperone-mediated autophagy. Science, 305, 1292-95.
40. Cunha, P.A. (2001) Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors. Neurochem. Int., 38, 107-125.
41. Darios, F., Corti, O., Lucking, C.B., Hampe, C., Muriel, M.P., Abbas, N., Gu, W.J., Hirsch, E.C., Rooney, T., Ruberg, M., Brice, A. (2003) Parkin prevents mitochondrial swelling and cytochrome C release in mitochondria dependant cell death. Hum. Mol. Genet., 12, 517-526.
42. Dawson, T.M., Dawson, V.L. (2003) Rare genetics mutations shed light on the pathogenesis of Parkinson's disease. J. Clin. Invest., 111, 145-151.
43. Dawson, V.L., Dawson, T.M. (1998) Nitric oxide in neurodegeneration. Prog. Brain Res., 118, 215-29.
44. de Rijk, M.C., Launer, L.J., Berger, K. (2000). Prevalence of Parkinson's disease in Europe: a collaborative study of population based cohorts. Neurology, 55, 1358-63.
45. Dekker, M., Bonifati, V., van Swieten, J., Leenders, N., Galjaard, R.J. (2003) Clinical features and neuroimaging of PARK7-linked parkinsonism. Mov. Disord., 18, 51-757.
46. Demasi, M., Davies, K.J. (2003) Proteasome inhibitors induce intracellular protein aggregation and cell death by an oxygen dependant mechanism. FEBS Lett., 542, 89-94.
47. Deumens, R., Blokland, A., Prickaerts, J. (2002) Modeling RD in rats: an evolution of 6- OH DA lesions of the nigrostriatal pathway. Exp. Neurol., 175, 303-317.
48. Dev, K.K., Hofele, K., Barbieri, S., Buchman, V.L., van der Putten, H. Part II (2003) α- synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology, 45, 14-44.
49. Dev, K.K., van der Putten, H., Sommer, B., Rovelli, G. Part I (2003) Parkin associated proteins and Parkinson's disease. Neuropharmacology, 45, 1-13.
50. Dewy Jr, R.B. (2004) Autonomic dysfunction in Parkinson's disease. Neurol. Clin., 22, S127-S139.
51. Di Fonzo, A., Rohe, C.F., Ferreira, J. (2005) A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet, 365, 412-415.
52. Diguet, E., Fernagut, P.O., Wei, X., Du Rouland, R., Gross, C., Bezard, E., Tison, F. (2004) Deleterous effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur. J. Neurosci., 19, 3266-3276.
53. Ding, T.T., Lee, S.J., Rochet, J.C., Lansbury, P.T.J. (2002) Annular α-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain derived membranes. Biochemistry, 41, 10209-10217.
54. Djaldetti, R., Melamed, E. (1996) Levodopa fluctuations in Parkinson's disease. Ann. Neurol., 390, 400-404.
55. 2b receptor involvement in the hypermobility effects of adenosine analogues in mice. Eur. J. Pharmacol., 168, 285-290.
56. Duan, W., Zhi, X., Landenheim, B., Yu, Q.S., Guo, Z., Oyler, J. (2002) p53 inhibitors preserve dopamine neurons and motor function in experimental Parkinsonism. Ann. Neurol., 52, 597-606.
57. Dubois, B., Pillon, B. (1997) Cognitive deficit in Parkinson's disease. J. Neurol., 244, 2-8.
58. Duda, J.E., Giasson, B.I., Chen, Q., Gur, T.L., Hartig, H.I., Stern, M.B. (2000) Widespread nitration pathological inclusions in neurodegenerative synucleinopathies. Am. J. Pathol., 157, 1439-45.
59. During, M.J., Kaplitt, M.G., Stern, M.P., Eidelberg, D. (2001) Subthalamic GAD gene transfer in Parkinson's disease patients who are candidates for deep brain stimulation. Hum. Gene Ther., 12, 1589-1591.
60. El-Agnaf, O.M., Paleologou, K.E., Greer, B., Abogrein, A.M., King, J.E., Salem, S.A., Fullwood, N.J. (2004) A strategy for designing inhibitors of αSN aggregation and toxicity as a novel treatment for PD and related disorders. FASEB J., 18, 1315-1317.
61. El-Agnaf, O.M., Irvine, G.B. (2002) Aggregation and neurotoxicity of α-synuclein and related peptides. Biochem. Soc. Trans., 30, 559-565.
62. Eldadah, B.A., Faden, A.T. (2000) Caspase pathways, neuronal apoptosis and CNS injury. J. Neurotrauma, 17, 811-829.
63. Eliezer, D., Kutluay, E., Bussell, R., Brown, G. (2001) Conformational properties of α- synuclein in its free and lipid-associated states. J. Mol. Biol., 307, 1061-1073.
64. Emerit, J., Edeas, M., Bricaire, F. (2004) Neurodegenerative diseases and oxidative stress. Biomed. Pharmacother., 58, 39-46.
65. Emilien, G., Maloteaux, J., Geurts, M., Hoogenberg, K., Cragg, S. (1999) Dopamine receptors-physiological understanding to therapeutic intervention potential. Pharmacol. Ther., 84, 133-156.
66. Emre, M. (2003) Dementia associated with Parkinson's disease. Lancet Neurol., 2, 229-37.
67. Fahn, S. (1996) Is levodopa toxic? Neurology, 47, S184-S195.
68. Fahn, S. (1998) Welcome news about levodopa, but uncertainty remains. Ann. Neurol., 43, 551-554.
69. Fahn, S.A. (1992) A pilot trial of high dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann. Neurol., 32, S128-S132.
70. Farrer, M., Maraganore, D.M., Lockhart, P., Singleton, A., Lesnick, T.G., de Andrade, M., West, A., de Silva, R., Hardy, J., Hernandez, D. (2001) α-synuclein gene haplotypes are associated with Parkinson's disease. Hum. Mol. Genet., 10, 1847-1851.
71. Farrer, M., Chan, P., Chen, R., Tan, L., Lincoln, S., Hernandez, D. (2001) Lewy bodies and Parkinsonism in families with Parkin mutations. Ann. Neurol., 50, 293-300.
72. Feng, Z.H., Wang, T.G., Li, D.D., Fung, P., Wilson, B.C., Liu, B., Ali, S.F., Langenbach, R., Hong, J.S. (2002) Cyclooxygenase-2 deficient mice are resistant to 1-methyl-4- phenyl-1,2,3,6 tetrahydropyridine induced damage of dopaminergic neurons in the substantia nigra. Neurosci. Lett., 329, 354-358.
73. Ferre, S., Von Euler, G., Johansson, B., Fredholm, B.B., Fuxe, K. Stimulation of high affinity adenosine A2 receptors decrease the affinity of dopamine D2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. USA, 88, 7238-7241.
74. Forono, L.S. (1996) Neuropathology of Parkinson's disease. J. Neuropathol. Expt. Neurol., 55, 259-272.
75. Foroud, T., Uniacke, S.K., Liu, L., Parkartz, N., Rudolph, A., Halter, C., Shults, C., Marder, K., Conneally, P.M., Nicholas, W.C. (2003) Heterozygosity for a mutation in the gene leads to later onset Parkinson's disease. Neurology, 60, 796-801.
76. Foster, G.A., Stringer, B.M.J. (2004) Cell based therapies for PD. Drug Discov. Today, 1, 43-49.
77. Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M.S., Shen, J., Takio, K., Iwatsubo, T. (2002) α-synuclein is phosphorylated in synuclepathy lesions. Nat. Cell Biol., 4, 160-164.
78. Funayama, M., Hasegawa, K., Ohta, E., Kawashima, N., Komiyama, M., Kowa, H., Tsuji, S., Obata, F. (2005) A LRRK 2 mutation as a cause factor for the parkinsonism in the original PARK 8 family. Ann. Neurol., 57, 918-921.
79. Furukawa, Y., Kish, S.J. (1999) Dopa-responsive dystonia: recent advances and remaining issues to be addressed. Mov. Disord., 14, 709-15.
80. Gelb, D.J., Oliver, E., Gilman, S. (1999) Diagnostic criteria for Parkinson's disease. Arch. Neurol., 56, 33-39.
81. George, J.M. (2002) The synucleins. Genome Biol., 3, 3002-3006.
82. Giasson, B.I., Muray, J.V.J., Trojanowski, J.Q., Lee, V.M. (2001) A hydrophobic stretch of 12 amino acid residues in the middle of α-synuclein is essential for filament stability. J. Biol. Chem., 276, 2380-2386.
83. Gilks, W.P., Abou-Sleiman, P.M., Gandhi, S., Jain, S., Singleton, A., Lees, A.J., Shaw, K., Bhatia, K.P., Bonifati, V. (2005) A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet, 365, 415-416.
84. Gill, S.S., Patel, N.K., Hotton, G.R., O'Sullivan, K. (2003) Direct brain infusion of GDNF in Parkinson's disease. Nat. Med., 9, 589-595.
85. Globe, L.I. (1991) Young onset Parkinson's disease: a clinical review. Neurology, 41, 168-73.
86. Gloeckner, C.J., Kink, N., Schumacher, A., Braun, R.J., O'Neil, E., Meitinger, T., Kolch, W., Prokishch, H., Ueffing, M. (2006) The Parkinson's disease causing LRRK2 mutations I2020T is associated with increased kinase activity. Hum. Mol. Genet., 15, 223-232.
87. Goldberg, A.L. (2003) Protein degradation and protection against misfolded or damaged proteins. Nature, 426, 895-9.
88. Gorell, J.M., Jhonson, C.C., Rybicki, B.A. (1990) Occupational exposure to manganese, copper, lead, iron, mercury and zinc and risk of Parkinson's disease. Neurotoxicology, 20, 239-48.
89. Gorell, J.M., Johnson, C.C., Rybicki, B.A., Peterson, E.L., Richardson, R.J. (1998) The risk of Parkinson's disease with exposure to pesticides, farming, well water and rural living. Neurology, 50, 1346-50.
90. Gorell, J.M., Peterson, E.L., Rybcki, B.A., Johnson, C.C. (2004) Multiple risk factors for Parkinson's disease. J. Neurol. Sci., 217, 169-174.
91. Gosavi, N., Lee, H.J., Lee, J.S., Patel, S., Lee, S.J. (2002) Golgi fragmentation occurs in the cells with protofibrillar α-synuclein aggregates and proceeds the formation of fibrillar inclusion. J. Biol. Chem., 277, 48984-92.
92. Green, J.G., Greenamyre, J.T. (1996) Bioenergetics and glutamate excitotoxicity. Prog. Neurobiol., 48, 613-34.
93. Greenamyre, J.T., Betarbet, R., Sherer, T.B. (2003) The rotenone model of Parkinson's disease: genes environment and mitochondria. Parkinsonism Relat. Disord., 9(Suppl. 2), 59-64.
94. Grune, T., Jung, T., Merker, K., Davies, K.J. (2004) Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid and aggreosomes during oxidative stress, aging and disease. Int. J. Biochem. Cell Biol., 36, 2579-2630.
95. Guillin, O., Diaz, J., Carrol, P., Griffen, N. (2001) BDNF controls D3 receptor expression and triggers behavioral sensitization. Nature, 411, 86-89.
96. Hague, R., Rogaeva, E., Hernandez, D., Gulick, C., Singleton, A., Hanson, M., Johnson, J., Weiser, R., Gallardo, M., Ravina, B., Gwinn-Hardy, K., Crawley, A., George- Hyslop, P.H., Lang, A.E. (2003) Early onset Parkinson's disease caused by compound heterozygous DJ 1 mutations. Ann. Neurol., 54, 271-274.
97. Hald, A., Lotharius, J. (2005) Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp. Neurol., 193, 279-290.
98. Hallelt, P., Standaert, D.G. (2004) Rationale for the use of NMDA receptor antagonists in Parkinson's disease. Pharmacol. Ther., 102, 155-174.
99. Hardy, J., Cookson, M.R., Singleton, A. (2003) Genes and Parkinson's disease. Lancet Neurol., 2, 221-28.
100. Hashimoto, M., Takenouchi, T., Rockenstein, E., Masliah, E. (2003) α-synuclein upregulates expression of caveolin-1 and down regulates extracellular signal regulated kinase activity in B1O3 neuroblastoma cells: role in the pathogenesis of PD. J. Neurochem., 85, 1468-1479.
101. Hatano, Y., Li, Y., Sato, K., Asakawa, S., Yamamura, Y., Tomiyama, H., Yoshino, H. (2004) Novel PINK1 mutations in early-onset parkinsonism. Ann. Neurol., 56, 424-427.
102. Hauser, R.A., Hubble, J.P. (2003) Istradefylline US001 study group. Randomized trial of adenosine A2A receptor antagonist istradefylline in advanced Parkinson's disease. Neurology, 61, 297-303.
103. Heidrich, K., Djarmati, A., Schater, N., Hering, R., Wellenbrock, C., Weiss, P.H., Bonifati, V., Schwinger, E. (2004) DJ 1 (PARK 7) mutations are less frequent that parkin (PARK 2) mutations in early onset Parkinson's disease. Neurology, 62, 389-394.
104. Hely, M.A., Fung, V.S.C., Morris, J.G. (2000) Treatment of PD. J. Clin. Neurosci., 7, 484-494.
105. Henderson, R., Kurlan, R., Kersyn, J.M., Como, P. (1992) Preliminary examination of comorbidity of anxiety and depression in Parkinson's disease. J. Neuropsychiatry Clin. Neurosci., 4, 257-64.
106. Hermann, A., Gerlach, M., Scharz, J., Starch, A. (2004) Neurorestoration in Parkinson's disease by cell replacement and endogenous regeneratioin. Exp. Opin. Biol. Ther., 4, 131-143.
107. Hershko, A., Ciechanover, A. (1998) The ubiquitin system. Ann. Rev. Biochem., 67, 425-479.
108. Hicks, A.A., Petursson, H., Jonsson, T., Stefansson, H., Johannsdotrir, H.S., Sainz, J. (2002) A suceptibility gene for late-onset idopathic Parkinson's disease. Ann. Neurol., 52, 549-555.
109. Hirsch, E.C., Mouatt, A., Thomassa, M. (1992) Expression of calbindin D 28K-like immunoreactivity in catecholaminergic cell groups of human midbrain normal distribution in Parkinson's disease. Neurodegeneration, 1, 83-93.
110. Hirsch, E.C., Faucheux, B.A. (1998) Iron metabolism and Parkinson's disease. Mov. Disord., 13, 39-45.
111. Hoehn, M.M., Yahr, M.D. (1967) Parkinson's disease: onset, progression and mortality. Neurology, 17, 427-42.
112. Holzmann, C., Kruger, R., Saecker, A.M., Schmitt, E., Schols, L., Berger, K., Reiss, O. (2003) Polymorphism of α-synuclein promoter: expression analysis and association studies in Parkinson's disease. J. Neurol. Trans., 110, 67-76.
113. Hoozemans, J.J., Veerhuis, R., Janssen, I., Janvan, E.I.K.E., Rozemuller, A.J.M., Eikelenboom, P. (2002) The role of cyclooxygenase 1 and 2 activity in prostaglandin E2 secretion by cultured human adult microglia: implication for Alzheimer's disease. Brain Res., 951, 218-226.
114. Hsu, L.J., Sagara, Y., Arroyo, A., Rockenstein, E., Sisk, A. (2000) α-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol., 157, 401-10.
115. Huai, Q., Sun, Y., Wang, H., Clain, L., Li, L., Rabinson, H., Ke, H. (2003) Crystal structure of DJ-1/RS and implication on familial Parkinson's disease. FEBS Lett., 549, 171-175.
116. Hughes, A.J., Daniel, S.E., Ben-Shlomo, Y., Lees, A.J. (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain, 125, 861-870.
117. Hyman, C., Hofer, M.B., Arde, Y.A., Juhar, M., Yancopoulos, G.D., Squinto, S.P., Lindsay, R.M. (1991) A BDNF is a neuropathic factor for dopaminergic neurons of the substantia nigra. Nature, 350, 230-232.
118. Imai, J., Yashiroda, H., Maruya, M., Yahara, I., Tanaka, K. (2003) Proteasomes and molecular chaperones: cellular machinery responsible for folding and destruction of unfolded proteins. Cell Cycle, 2, 585-590.
119. Imai, Y., Soda, M., Takahashi, R. (2000) Parkin suppresses unfolded protein stress- induced cell death through E3 ubiquitin-protein ligase activity. J. Biol. Chem., 275, 35661-35664.
120. Imai, Y., Soda, M., Inoue, H., Hattori, N., Mizuono, Y., Takahashi, R. (2001) An unfolded putative transmembrane polypeptide which can lead to endoplasmic reticulum stress, a substrate for parkin. Cell, 105, 891-902.
121. Inzelberg, R., Schechtman, E., Paleacu, D. (2002) Onset age of Parkinson's disease. Am. J. Med. Genet., 111, 459-60.
122. Jankovic, J. (1989) Essential tremor and Parkinson's disease. Ann. Neurol., 25, 211-12.
123. Jenco, J.M., Rawlingson, A., Daniels, B., Morris, A.J. (1998) Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by α- and β-synucleins. Biochemistry, 37, 4901-4909.
124. Jendroska, K., Olasode, D.J. (1994) Incidental Lewy body disease in black Africans. Lancet, 344, 882-3.
125. Jenner, P., Marsden, C.D. (1992) Motor activity following the administration of selective D1 and D2 dopaminergic drugs to MPTP treated common marmosets. Psychopharmacol (Berlin), 109, 49-56.
126. Jenner, P. (2005) A novel dopamine agonist for the transdermal treatment of PD cases. Neurology, 65, S3-S5.
127. Jenner, P. (1998) Oxidative mechanism in nigral cell death in Parkinson's disease. Mov. Disord., 13, 24-34.
128. Jenner, P. (2003) Oxidative stress in Parkinson's disease. Ann. Neurol., 53, S26-S36.
129. Jenner, P. (1995) The rational use of dopamine agonist in PD. Neurology, 45, S6-S12.
130. Jimenz, F.J., Garcia-Ruiz, P.J., Molina, J.A. (1997) Drug induced movement disorders. Drug Saf., 16, 180-204.
131. Jo, E., McLaurin, J., Yip, C.M., St. Geroge-Hyslop, P., Fraser, P.E. (2000) synuclein membrane interaction and lipid specificity. J. Biol. Chem., 275, 34328-34334.
132. Johnson, W.G., Hodge, S.E., Duvoisin, R. (1990) Twin studies and the genetics of Parkinson's disease: a reappraisal. Mov. Disord., 5, 187-94.
133. Kase, H., Mori, A., Jenner, P. (2004) Adenosine A2A receptor antagonists beyond dopaminergic therapies for Parkinson's disease. Drug Discov. Today, 1, 51-57.
134. Katsuse, O., Iseki, E., Marui, W., Kosaka, Y. (2003) Developmental stages of cortical Lewy bodies and their reduction to axonal transport blockage in brains of patients with demential with Lewy bodies. J. Neurol. Sci., 211, 29-35.
135. Katzenschlager, R., Hughes, A., Evans, A., Manson, A.J., Hoffman, M., Swinn, L., Watt, H., Bhatia, K., Quinn, N., Lees, A.J. (2005) Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single- dose challenges. Mov. Disord., 20, 151-157.
136. Kennedy, L.J., Moore, Jr. K., Caulfield, J.L., Tannenbaun, S.R., Dedon, P.C. (1997) Quantitation of 8-oxoguanine and strand breaks produced by four oxidising agents. Chem. Res. Toxicol., 10, 386-392.
137. Khan, F.M., Saha, M., Chakrabarti, S. (2001) Dopamine induced protein damage in mitochondrial- synaptosomal fraction in rat brain. Brain Res., 895, 245-249.
138. Kim, T.D., Paik, S.R., Yang, C.H., Kim, J. (2000) Structural changes in α-synuclein affect its chaperone-like activity in vitro. Protein Sci., 9, 2489-2496.
139. Kim, T.D., Paik, S.R., Yang, C.H. (2002) Structural and functional implication of C- terminal regions of α-synuclein. Biochemistry, 41, 13782-13790.
140. Ko, L., Mehta, N.D., Farrer, M., Eassen, C., Hussey, J. (2000) Sensitization of neuronal cells to oxidative stress with mutated human α-synuclein. J. Neurochem., 75, 2546-54.
141. Koller, W.C. (1984) Sensory symptoms in Parkinson's disease. Neurology, 34, 1957-59.
142. Kordower, J.H., Emborg, M.E., Bloch, J., Ma, S.Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.Y., Palfi, S. (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science, 290, 767-73.
143. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graber, M., Kosel, S., Przuntek, H., Epplen, J.T., Schols, L., Reiss, O. (1998) Ala30 Pro mutation in the gene encoding α- synuclein in Parkinson's disease. Nat. Genet., 18, 106-108.
144. Kuhn, D.M., Arthur, Jr. A.E., Thomas, D.M., Elferink, L.A. (1999) Tyrosine hydroxylase is inactivated by catechol-quinones and converted to redoxcycling quinoprotein: possible relevance to Parkinson's disease. J. Neurochem., 279, 48384-96.
145. Kuroda, Y., Mitsui, T., Kunishige, M., Shono, M., Akaike, M., Azuma, H., Matsumoto, T. (2006) Parkin enhances mitochondrial biogenesis in proliferating cells. Hum. Mol. Genet., 1, 883-95.
146. Laihinen, A., Ruottien, H., Rinne, J.O., Haaparanta, M., Bergman, J., Salin, O. (2000) Risk of Parkinson's disease: twin studies for the detection of asymptomic subject using 6 fluro dopa PET. J. Neurol., 247, 110-3.
147. Lang, A.E., Lozano, A.M. (1998) Parkinson's disease. N. Eng. J. Med., 339, 1044-53.
148. Langston, J.W., Ballard, P.A., Tetrud, J.W., Irwin, I. (1983) Chronic Parkinsonism in humans due to a product of mepridine analog synthesis. Science, 219, 979-80.
149. Lashuel, H.A., Hartley, D., Petre, B.M., Waltz, T., Lansbury, P.T.J. (2002) Neurodegenerative disease: amyloid pores from pathogenic mutation. Nature, 418, 291.
150. Le, W.D., Xu, P., Jankovic, J., Jiang, H., Appel, S.H., Smith, R.G., Vassilatis, D.K. (2003) Mutations in NR4A2 associated with familial Parkinson's disease. Nat. Genet., 33, 85-89.
151. Lee, M., Hyuan, D., Halliwell, B., Jenner, P. (2001) Effect of the over expression of wild type mutant α-synuclein on cell susceptibility to insult. J. Neurochem., 76, 998-1009.
152. Lee, W., Rowe, D., Yie, W., Ortiz, I., He, Y., Apple, S.H. (2001) Microglial activation of dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J. Neurosci., 21, 8447-8455.
153. Leroy, E., Baer, R., Auburgen, G., Leube, B., Ulm, G. (1998). The ubiquitin pathway in Parkinson's disease. Nature, 395, 451-452.
154. Lilienfield, E.D., MarderCote, L., Tang, M., Mayeux, R. (1993) Projected neurodegenerative disease mortality in US, 1990-2040. Neuroepidemiology, 12, 219-28.
155. Lindersson, E., Beedholm, R., Hojrup, P., Moos, T., Gai, W. (2004) Proteasomal inhibition of α-synuclein filaments and oligomers. J. Biol. Chem., 279, 12924-34.
156. Lohmann, E., Periquet, M., Bonifati, V., Wood, N.W., De Michele, G., Bonnet, A.M. (2004) How much phenotypic variation can be attributed parkin genetype? Ann. Neurol., 56, 336-341.
157. Lotharius, J., Brundin, B. (2002) Pathogenesis of Parkinson's disease: dopamine, vesicles and α-synuclein. Nat. Rev. Neurosci., 3, 1-11.
158. Lotharius, J., Brundin, P. (2002) Impaired dopamine storage resulting from α-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum. Mol. Genet., 11, 2395-2407.
159. Louis, E.D., Mareter, K., Cote, L., Tang, M., Mayeux, R. (1997) Mortality from Parkinson's disease. Arch. Neurol., 54, 260-264.
160. Lucking, C.B., Durr, A., Bonifati, V., Vaughan, J., De Michele, G. (2000) Association between early onset Parkinson's disease and mutations in the parkin gene. N. Eng. J. Med., 342, 1560-67.
161. Lwin, A., Orvisky, E., Gokr-Alpan, O., LaMarca, M.E., Sidransky, E. (2004) Glucocerebroside mutations in the subjects with parkinsonism. Mol. Genet. Metab., 81, 70-73.
162. Maino, M.J., Valenti, O., Cann, P.J. (2003) Glutamate receptors and Parkinson's disease: opportunities for intervention. Drugs Aging, 20, 377-397.
163. Manning-Bog, A.B., McComack, A.L., Li, J., Uversky, V.N., Fink, A.L., Di Monte, D.A. (2002) The herbicide paraquat causes upregulation and aggregation of α-synuclein in mice:paraquat and α-synuclein. J. Biol. Chem., 277, 1641-1644.
164. Maoi, M., Marugam, W. (2004) Dopamine derived salsolinol derivatives as exogenous MAO inhibitor: occurrence, metabolism and function in human brains. Neurotoxicology, 25, 193-204.
165. Marder, K., Tang, M.X., Mejia, H., Alfaro, B., Cote, L. (1996) Risk of Parkinson's disease among fist degree relatives: a community based study. Neurology, 47, 155-60.
166. Marin, C., Papa, S., Engber, T.M., Bonastre, M. (1996) Levodopa induced motor response alterations in Parkinsonian rats. Brain Res., 736, 202-205.
167. Marsh, L. (2000) Neuropsychiatric aspects of Parkinson's disease. Psychosomatics, 41, 15-23.
168. Marti-Masso, J.F., Poza, J.J., Lopez de Munain, A. (1996) Drugs inducing or aggrevating Parkinsonism: a review. Therapie, 5, 568-577.
169. Martinez-Martin, P., Gil-Nagel, A., Gracia, L.M., Germez, J.B., Martinez-Sarries, J., Bermejo, F. (1994) Unified PD rating scale characteristics and structure. Mov. Disord., 9, 76-83.
170. Marx, F.P., Holzmann, C., Strauss, K.M. (2003) Identification and functional characterization of novel R621C mutations in the synphilin-1 gene in PD. Hum. Mol. Genet., 12, 1223-1231.
171. Masliah, E., Rockenstein, A., Adame, E., Alferd, M., Crews, L., Alashimoto, M., Secubent, P., Lee, M. (2005) Effects of αSN immunization in mouse model of PD. Neuron, 46, 857-868.
172. Mata, I.F., Lockhart, P.J., Farrer, M. (2004) Parkin genetics: one model for Parkinson's disease. Hum. Mol. Genet., 13, R27-33.
173. McCall, R.B., Lookingland, K.J., Bedard, P.J., Huff, R.M. (2005) Sumanirole a highly dopamine D2 selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal model of Parkinson's disease. J. Pharmacol. Exp. Ther., 314, 1248-1256.
174. McGeer, P.L., Schwab, C., Parent, A., Doudet, D. (2001) Presence of reactive microglia in monkey substantia nigra after MPTP administration. Ann. Neurol., 169, 219-230.
175. McLean, P.J., Klucken, J., Shin, Y., Hyman, B.T. (2004) Geldanamycin induces Hsp 70 and prevents..SN aggregation and toxicity in vitro. Biochem. Biophys. Res. Commun., 321, 665-669.
176. McNaught, K.S., Olanow, C.W. (2003) Proteolytic stress: a unifying concept in the etiopathogenesis of familial and sporadic Parkinson's disease. Ann. Neurol., 53, S73-86.
177. McNaught, K.S., Olanow, C.W. (2006) Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol. Aging, 27, 530-545.
178. Michel, P.P., Hefti, F. (2004) Toxicity of 6-hydroxy dopamine and dopamine for dopaminergic neurons in culture. J. Neurosci. Res., 26, 428-35.
179. Miller, T.W., Messer, A. (2005) Intrabody applications in neurological disorders: progress and future prospects. Mol. Ther., 12, 394-401.
180. Moghal, S., Rajput, A.H., D'Arcy, C., Rajput, R. (1994) Prevalence of movement disorder in elderly community residents. Neuroepidemiology, 13, 175-178.
181. Mogi, M., Harada, M., Kondo, T., Riederer, P., Inayaki, H., Minami, M. (1996) Interleukin 1-beta, interleukin 6, epidermal growth factor and transforming growth factor-alpha are activated in ventricular cerebrospinal fluid in juvanile parkinsonism and Parkinson's disease. Neurosci. Lett., 211, 13-16.
182. Molho, E.S., Facter, S.A., Weiner, W.T., Sanchez-Ramas, J.R., Singer, C., Shulman, L., Brown, D., Sheldon, C. (1995) The use of pramipexole a novel dopamine agonist in advanced Parkinson's disease. J. Neurol. Transm., S45, 225-230.
183. Moore, D.J., West, A.B., Dawson, V.L., Dawson, T.M. (2005) Molecular pathophysiology of Parkinson's disease. Ann. Rev. Neurosci., 28, 57-87.
184. Moore, D.J., Zhang, L., Dawson, T.M., Dawson, V.L. (2003) A missense mutation (L166P) is DJ-1 linked to familial Parkinson's disease confers reduced protein stability and impairs homo-oligomerization. J. Neurochem., 87, 1558-67.
185. Morris, H.R. (2005) Genetics of Parkinson's disease. Ann. Med., 37, 86-96.
186. Muchowski, P.J. (2002) Protein misfolding, amyloid formation and neurodegeneration: a critical role for molecular chaperones? Neuron, 35, 9-12.
187. Murphy, T.H., Miyamoto, M., Sastre, A., Achnaar, R.L., Coyle, J.T. (1989) Glutamate toxicity in neuronal cell line involves inhibition of cysteine transport leading to oxidative stress. Neuron, 2, 1547-58.
188. Muthane, U.B., Swamy, H.S., Satischandra, P., Subhash, M.N., Rao, S., Subbakrishna, D. (1994) Early onset Parkinson's disease: are juvenile and young onset different? Mov. Disord., 9, 539-544.
189. Newman-Tancredi, A., Cussac, D., Audinot, V., Nicolas, J., De Ceuninck, F., Boutin, J.A., Millan, M.J. (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and α(1)/α(2)-adrenoceptor. J. Pharmacol. Exp. Ther., 303, 805-814.
190. Niehaus, I., Lange, J.H. (2003) Endotoxins: is it an environmental factor in the cause of Parkinson's disease? Occup. Environ. Med., 60, 378.
191. Niki, T., Takahashi-Nik, A., Taira, T., Iguchi-Agira, S.M., Agira, H. (2003) DJBP: a novel DJ 1 binding protein, negatively regulates the androgen receptor by recruiting histome deacetylase complex and DJ 1 antagonizes this inhibition by abrogation of this complex. Mol. Cancer Res., 1, 247-261.
192. Norris, F.H., Giasson, B.I., Hodara, R., Xu, S., Trojanowski, J.Q. (2005) Reversible inhibition of αSN fibrillization by dopaminochrome mediated conformational alterations. J. Biol. Chem., 280, 21212-21219.
193. Olanow, C.W. (2000) Tolcapane and hepatic effects. Arch. Neurol., 57, 263-267.
194. Olanow, C.W., Schapira, A.H., LeWitt, P.E., Kieburtz, K., Sauer, D., Olivieri, G., Pohlmann, H., Hubble, J. (2006) TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol., 5, 1013-1020.
195. Oliveira, S.A., Scott, W.K., Martin, E.R., Nance, M.A., Watt, R.L., Hubble, J.P., Koller, W.C., Pahwa, R. (2003) Parkin mutations and susceptibility alleles in late onset Parkinson's disease. Ann. Neurol., 53, 624-629.
196. Orr, C.F., Rowe, D.B., Halliday, G.M. (2002) An inflammatory review of Parkinson's disease. Prog. Neurobiol., 68, 325-340.
197. Orth, M., Schapira, A.H. (2002) Mitochondrial involvement in Parkinson's disease. Neurochem. Int., 40, 53-41.
198. Ostrerova, V., Petrucelli, L., Farrer, M., Mehta, N., Choi, P., Hardy, J., Wolozin, B. (1996) α-synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci., 19, 5782-5791.
199. Paisan-Ruiz, C., Jain, S., Evans, E.W., Gilks, W.P., Simon, J. (2004) Cloning of the gene containing mutations that cause PARK 8 linked Parkinson's disease. Neuron, 44, 595-600.
200. Pals, P., Lincoln, S., Manning, J., Heckman, M., Skipper, L. (2004) α-synuclein promoter confers susceptibility to Parkinson's disease. Ann. Neurol., 56, 591-95.
201. Pankratz, N., Nichols, W.C., Uniacke, S.K., Halter, C., Rudolph, A., Shults, C. (2003) Significant linkage of Parkinson's disease to chromosome 2q36-37. Am. J. Hum. Genet., 72, 1053-1057.
202. Paolini, M., Sapone, A., Gonzalez, E.J. (2004) Parkinson's disease, pesticides and individual vulnerability. Trends Pharmacol. Sci., 25, 124-129.
203. Park, S.M., Jung, H.Y., Kim, T.D., Park, J.H., Yang, C.H., Kim, J. (2002) Distinct roles of N-terminal binding domain and C-terminal solubilizing domain of α-synuclein, a molecular chaperone. J. Biol. Chem., 277, 28512-28520.
204. Parkinson's Study Group. (2001) Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of the remacemide in advanced Parkinson's disease. Arch. Neurol., 58, 1660-1668.
205. Parkinson's Study Group. (1996) Impact of deprenyl and tocopherol treatment of Parkinson's disease in DATATOP patients requiring levodopa. Ann. Neurol., 39, 37-45.
206. Parkinson's Study Group. (1996) Lazabenide. Ann. Neurol., 39, 37-45.
207. Parkinson's Study Group. (2004) The safety and tolerability of a mixed linkage kinase inhibitor (CEP-1347) in PD. Neurology, 62, 330-332.
208. Payami, H., Larsen, K., Bernard, S., Nutt, J. (1994) Increased risk of Parkinson's disease in parents and siblings of patients. Ann. Neurol., 36, 659-69.
209. Perez, R.G., Waymire, J.C., Lin, E., Liu, J.J., Guo, F., Zigmond, M.J. (2002) A role for α-synuclein in the regulation of dopamine biosynthesis. J. Neurosci., 22, 3090-3099.
210. Periquet, M., Lucking, C., Vaughan, J., Bonifat, V., Durr, A., De Michele, G., Horstink, M, Farrer, M. (2001) Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, where as point mutations may result from founder effects. Am. J. Hum. Genet., 68, 617-627.
211. Perlow, M.J., Fred, W.J., Hoffer, B.J., Seiger, A., Olsen, L., Wyatt, R.J. (1979) Brain grafts reduce motor abnormalities produced destruction of nigrostriatal dopamine system. Science, 204, 643-647.
212. Perrin, R.J., Woods, W.S., Clayton, D.F., George, J.M. (2000) Interaction of human α-synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. J. Biol. Chem., 275, 34393-34398.
213. Petrucelli, L., O'Farrel, L., Lockhart, P.J., Baptista, M., Kehoe, K., Vink, L., Choi, P., Wolozinn, B., Farrer, M., Hardy, J., Cookson, M.R. (2002) Parkin protects against the toxicity associated with mutant α-synuclein: proteasome dysfunction selectively affects catecholaminergic neuron, Neuron, 36, 1007-1019.
214. 18F-DOPA PET. Adv. Neurol., 80, 227-31.
215. Pickart, C.M. (2001) Mechanisms of underlying ubiquitination. Ann. Rev. Biochem., 70, 503-533.
216. Pyle, A., Foltynie, T., Tiangyou, W. (2005) Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD. Ann. Neurol., 57, 564-67.
217. Quinn, N.P., Koller, W.C., Lang, A.E., Marsden, C.D. (1986) Painful Parkinson's disease. Lancet, 1, 1366-69.
218. Rajput, A.H. (1992) Frequency and cause of Parkinson's disease. Can. J. Neurol. Sci., 19 (Suppl. 1), 103-107.
219. Rascol, O., Brooks, D.J., Korczyn, A.D., De Deyn, P.P., Clarke, C.E., Lang, A.E. (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N. Engl. J. Med., 342, 1484-1491.
220. Ravikumar, B., Vacher, C., Berer, Z., Davies, J.E., Luo, S. (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington's disease. Nat. Genet., 36, 589-595.
221. Recchia, A., Debetto, P., Negro, A., Guidolin, D., Skaper, S., Giusti, P. (2004) α-synuclein and Parkinson's disease. FASEB J., 18, 617-626.
222. Rideout, H.J., Stefanis, L. (2001) Caspase inhibitors: a potential therapeutic strategy in neurological diseases. Histo. Histopathol., 16, 895-908.
223. Ross, O.A., McCormack, R., Maxwell, L.D. (2003) mt4216C variant in linkage with the mtDNA TJ cluster may confer a susceptibility to mitochondrial dysfunction resulting in an increased risk of Parkinson's disease in the Irish. Exp. Gerontol., 38, 397-405.
224. Sackett, D.L. (1979) Bias in analytical research. J. Chronic. Dis., 32, 51-63.
225. Samii, A., Letwin, S.R., Calne, D.B. (1998) Prospects for new drug treatment in idiopathic Parkinsonism. Drug Discov. Today, 3, 131-140.
226. Samii, A., Nutt, J.G., Ransom, B.R. (2004) Parkinson's disease. Lancet, 363, 1783-93.
227. Schapira, A.H., Olanow, C.W. (2004) Neuroprotection in Parkinson's disease mysteries, myths and misconception. JAMA, 291, 358-364.
228. Scheiden, W.L., Hershey, L.A., Vena, J.E., Holmulund, T., Marshall, J.R., Freudenhein, T. (1997) Dietary antioxidants and other dietary factors in the etiology of PD. Mov. Disord., 12, 190-196.
229. Schneider, J.S., Denaro, F.J. (1988) Astrocytic responses to the dopaminergic neurotoxin MPTP in cat and mouse brain. J. Neuropathol. Exp. Neurol., 47, 452-458.
230. Schulz, J.B., Lindenau, J., Seyfried, J., Dichgans, J. (2000) Glutathione, oxidative stress and neurodegeneration. Eur. J. Biochem., 267, 4904-4911.
231. Semchuk, K.M., Love, E.J., Lee, R.C. (1992) Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology, 42, 1328-1335.
232. Shachar, D.B., Kahana, N., Kampel, V., Warshawsky, A., Youdim, M.B. (2004) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6- hydroxydopamine lesion in rats. Neuropharmacology, 46, 254-263.
233. Shamato-Nagai, M., Maruyama, W., Kato, Y., Isobe, K., Tanaka, M., Naoi, M. (2003) An inhibitor of complex I rotenone inactivates proteasome by oxidative modification and induces aggregation of oxidized protein in SH-SY5Y cells. J. Neurosci. Res., 74, 589-97.
234. 2. Free Radic. Biol. Med., 34, 521-530.
235. Shen, J., Cookson, M.R. (2004) Mitochondria and dopamine - new insights into recessive parkinsonism. Neuron, 43, 301-304.
236. Sherman, M.Y., Goldberg, A.L. (2001) Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron, 29, 15-32.
237. Shimura, H., Hattori, N., Kubo, S., Mizuno, Y., Asakwa, S., Minoshima, S., Shimuzu, N., Iwai, K., Chiba, T. (2000) Familial PD gene product parkin is an ubiquitin-protein ligase. Nat. Genet., 25, 302-305.
238. Shimura, H., Schlossmacher, M.G., Hattori, N., Frosch, M.P., Trockenbacher, A., Schneider, R. (2001) Ubiquitination of a new form of α-synuclein by parkin from human brain: implications for Parkinson's disease. Science, 293, 263-269.
239. Shrag, A. (2004) Psychiatric aspects of Parkinson's disease - an update. J. Neurol., 251, 795-804.
240. Shubert, V., Anton, L.C., Gibbs, J., Norbury, C.C., Yewdell, J.W., Bennink, J.R. (2000) Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature, 404, 770-774.
241. Shutts, C.W., Oakes, D., Kieburtz, K., Beal, M.E., Hao, S.R. (2002) Effects of coenzyme Q10 in early Parkinson's disease: evidence of slowing the functional decline. Arch. Neurol., 59, 1541-1550.
242. Silvestri, L., Caputo, V., Bellacchi, E., Atorino, L., Dallapiccola, B., Valente, E.M., Casai, G. (2005) Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum. Mol. Genet., 14, 3477-3492.
243. Singleton, A.B., Farrer, M., Jhonson, J. (2003) α-synuclein locus triplication causes Parkinson's disease. Science, 302, 481.
244. Sion, J., Dexter, D.T., Lee, A.J., Daniel, S., Agid, Y. (1994) Alternation in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol., 36, 348-355.
245. Skipper, L., Farrer, M. (2002) Parkinson's genetics: molecular insights for the new millennium. Neurotoxicology, 23, 503-514.
246. Smith, C.A., Gough, A.C., Leigh, P.N. (1992) Debrisoquin hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet, 339, 1375-1377.
247. Snyder, H., Mensah, K., Theisler, C., Lee, J., Matouschek, A., Wolozin, B. (2003) Aggregated and monomeric α-synuclein bind S6 proteasomal protein and inhibit proteasomal function. J. Biol. Chem., 278, 11753-59.
248. Sofic, E., Riderer, P., Heinsen, H., Beckmann, H., Reynolds, G.P. (1988) Increased Iron (III) and total iron content in postmortem SN of Parkinsonian brain. J. Neurol. Transm., 74, 199-205.
249. Sokoloff, P., Schwartz, J.C., Novel dopamine receptors: half a decade later. Trends Pharmacol. Sci., 16, 270-275.
250. Spillantini, M.G., Crowther, R.A., Jakes, R., Hasegawa, M., Goedert, M. (1998) α-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA, 95, 6469-6473.
251. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanwoski, J.Q., Jakes, R., Goedert, M. (1997) α-synuclein in Lewy bodies. Nature, 388, 839-840.
252. Stacy, M. (2002) Sleep disorders in Parkinson's disease: epidemiology and management. Drugs Aging, 19, 733-39
253. Stern, M.B., Marck, K.L., Friedman, J., Hauser, R.A., Lewitt, P.A., Tarsy, D. (2004) Double blind randomized controlled trials of rasagilin as monotherapy in early Parkinson's patients. Mov. Disord., 19, 916-923.
254. Stokes, A.H., Hastings, T.G., Vrana, K.E. (1999) Cytotoxic and genotoxic potential of dopamine. J. Neurosci. Res., 55, 659-665.
255. Stoof, J.C., Booij, J., Drukcarch, B. (1992) Amantadine as N-methyl-Daspartic acid receptor antagonist: new possibilities for therapeutic applications? Clin. Neurol. Neurosurg., 94, S4-S6.
256. Szenasi, G., Harsing Jr, L.G. (2004) Pharmacology and perspective therapeutic usefulness of negative allosteric modulators of AMPA receptors. Drug Discov. Today, 1, 69-76.
257. Taanman, J.W., Schapira, A.H. (2005) Analysis of the trinucleotide CAG repeat from the DNA polymerase gamma gene (POLG) in patients with Parkinson's disease. Neurosci. Lett., 376, 56-59.
258. Tabrizi, S.J., Orth, M., Wilkinson, J.M., Taanman, J.W., Warner, T.T., Cooper, J.M., Schapira, A.H. (2000) Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum. Mol. Genet., 9, 2683-9.
259. Taira, T., Saito, Y., Niki, T., Iguchi-Ariga, S.M., Takahashi, K., Ariga, H. (2004) DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep., 5, 213-218.
260. Takahashi, K., Taira, T., Niki, T., Seino, C., Iguchi-Ariga, S.M.M., Ariga, H. (2001) DJ-1 positively regulates androgen receptor by imparing the binding of PISAXα to the receptor. J. Biol. Chem., 276, 37556-37563.
261. Tanner, C.M., Ottman, R., Goldman, S.M., Ellenberg, J., Chan, P., Mayeux, R., Langsten, J.W. (1999) Parkinson's disease in twin: an etiologic study. JAMA, 281, 341-346.
262. Tanuka, Y., Engelender, S., Igarashi, S., Rao, R.K., Wanner, T. (2001) Inducible expression of mutant α-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependant apoptosis. Hum. Mol. Genet., 10, 919-26.
263. Taylor, J.P., Mata, I.F., Farrer, M.J. (2006) LRRK 2: a common pathway for parkinsonism pathogenesis and prevention. Trends Mol. Med., 12, 76-82.
264. Teismann, P., Tieu, K., Choi, D.K., Wu, D.C., Naini, S., Hynot, M., Jackson-Lewis, V.V., Przedborski, S. (2003) Cyclooxygenase 2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. USA, 100, 5473-5478.
265. Thobios, S., Delamarre-Damier, F., Derkindern, P. (2005) The treatment of motor dysfunction in PD: an overview. Clin. Neurol. Neurosurg., 107, 269-281.
266. Twelves, D., Perkins, K.S., Counsell, C. (2003) Systematic review of incidence of studies of Parkinson's disease. Mov. Disord., 18, 19-31.
267. Ueda, K., Fukushima, H., Masliah, E., Xia, Y., Twai, A., Yoshimoto, M., Otero, D.A., Kondo, J., Ihara, Y., Saitoh, T. (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 90, 11282-11286.
268. Uversky, V.N., Lee, H.J, Li, J., Fink, A.L., Lee, S.J. (2001) Stabilization of partially folded conformation during α-synuclein oligomerization in both purified and cytosolic preparations. J. Biol. Chem., 276, 43495-43498.
269. Uversky, V.N., Li, J., Fink, A.L. (2001) Metal triggered structural transformation, aggregation and fibrillation of human α-synuclein: A molecular link between Parkinson's disease and heavy metal exposure. J. Biol. Chem., 276, 44284-44296.
270. Uversky, V.N., Li, J., Fink, A.L. (2001) Pesticides directly accelerate the rate of α-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett., 500, 105-108.
271. Uversky, V.N., Li, J., Fink, A.L. (2001) Trimethylamine-N-oxide induced folding of α-synuclein. FEBS Lett., 509, 31-35.
272. Vaamonde, J., Luquin, M.R., Obeso, J.A. (1991) Subcutaneous lisuride infusion in Parkinson's disease, response to chronic administration in 34 patients. Brain, 114, 601-614.
273. Valente, E.M., Salvi, S., Ialango, T., Marogiu, R., Elia, A., Caputo, V., Romito, L. (2004) PINK1 mutations are associated with sporadic early onset parkinsonism. Ann. Neurol., 56, 336-341.
274. Valente, M.J., Lansbury, P.T.J. (2002) Vesicle permiabilization by protofibrillar α-synuclein is sensitive to Parkinson's disease linked mutations and occurs by a pore-like mechanism. Biochemistry, 41, 4595-4602.
275. Waldmeir, P.C., Tatton, W.G. (2004) Interrupting apoptosis in neurodegenerative disease potential for effective therapy? Drug Discov. Today, 9, 210-218.
276. Walsh, D.M., Hartley, D.M., Kusumoto, Y., Fezoui, Y., Condron, M.M., Lomakin, A. (1999) Amyloid beta-protein fibrillogenesis structure and biological activity of protofibrillar intermediates. J. Biol. Chem., 274, 25945-25952.
277. Wang, X., Zhu, S., Drozda, M., Zhang, W., Stavrovskaya, I.G., Caltaneo, E., Ferrante, R.J., Kristol, B.S., Friedlanda, R.M. (2003) Minocycline inhibits caspase-independent and dependant mitochondrial cell death pathways in models of Huntington's disease. Proc. Natl. Acad. Sci. USA, 100, 10483-10487.
278. Ward, C.D., Duvoisin, R.C., Ince, S.E., Nutt, J.D., Eldridge, R., Calne, D.P. (1983) Parkinson's disease in 65 pairs of twins and in a set of quadreuplets. Neurology, 33, 815-24.
279. Welsh, M. (2004) Parkinson's disease and quality of life: issues and challenges beyond motor symptoms. Neurol. Clin., 22, S141-S148.
280. West, A.B., Maraganore, D., Crook, J. (2002) Functional dissociation of parkin gene promoter with idiopathic Parkinson's disease. Hum. Mol. Genet., 11, 2787-2792.
281. Williams, M., Wright, S., Lloyd, G.K. (1997) Improved therapies for Parkinson's disease: life beyond dopamine D2/D3 receptor agonist. Trends Pharmacol. Sci., 18, 307-310.
282. Xu, J., Kao, S.Y., Lee, F.J., Song, L.W., Yanker, B.A. (2002) Dopamine dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson's disease. Nat. Med., 8, 600-606.
283. Yamamoto, M., Sakamoto, N., Iwai, A., Yatsugi, S., Hidaka, K., Naguchhi, K., Yuasa, T. (1993) Protective actions of YM737, a new glutathione analogue against cerebral ischemia in rats. Res. Commun. Chem. Pathol. Pharmacol., 81, 221-232.
284. Yang, L., Calingasan, N.Y., Chen, J., Ley, J.J., Becker, D.A. (2005) A novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities. Exp. Neurol., 191, 86-93.
285. Yokata, T., Sugawara, K., Ito, K., Takahashi, R., Ariga, H., Mizusawa, H. (2003) Downregulation of DJ-1 enhances cell death by oxidative stress, ER stress and proteasome inhibition. Biochem. Biophy. Res. Commun., 312, 1342-1348.
286. Yu, W.H., Kumar, A., Peterhoff, C., Kulnane, L.S., Vachiyama, Y. (2004) Autophagic vacuoles are enriched in amyloid precursor protein secretase activities: implications for beta-amyloid peptides over production and localization in Alzheimer's disease. Int. J. Biochem. Cell Biol., 36, 2531-2540.
287. Yuan, J., Yanker, B.A. (2000) Apoptosis in the nervous system. Nature, 407, 802-809.
288. Zarranz, J.J., Alegre, J., Gimez-Esteban, J.C., Lezeano, E., Ross, R., Ampuero, I., Vidal, L., Hoenicka, J., Roriguez, O. (2004) The new mutation E46K of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol., 55, 164-173.
289. Zhang, Y., Gao, J., Chung, K.K., Huang, H., Dawson, V.L., Dawson, T.M. (2000) Parkin function as an E2 dependent ubiquitin protein ligase and promotes the degradation of the synaptic vesicle associated protein CDCrel 1. Proc. Natl. Acad. Sci. USA, 97, 13354-59.
290. Zhang, Z.X., Roman, G.C. (1993) Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology, 12, 195-208.
291. Zhang, L., Dawson, V.L., Bricaire, F. (2006) Role of nitric oxide in Parkinson's disease. Pharmacol. Ther., 109, 33-41.
292. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J. (2004) Mutations in LRRK2 cause autosomal dominant parkinsonism with pleomorphic pathology. Neuron, 44, 601-607.